Advertisement

Endo Health Solutions today announced that its Qualitest subsidiary has completed the acquisition of privately held Boca Pharmacal, a specialty pharmaceutical company, for approximately $225 million in cash.  Boca Pharmacal is a specialty generics company that focuses on niche areas, commercializing and developing products in categories that include: controlled substances, semisolids, and solutions.  Boca Pharmacal's commercial footprint and R&D pipeline is expected to be a strong complement to Qualitest. The transaction will be financed with Endo's current cash on hand.

Advertisement
Advertisement